Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Antisera have been raised to the Fv fragment derived from a mouse alpha/lambda myeloma. These had different reactivities for Fv and mouse immunoglobulin and two of them appeared to detect v region framework determinants on normal mouse immunoglobulins. A large proportion of mouse lymphocytes were shown to have Fv determinants on the surface which was part of the B-lymphocyte antigen receptor. Most of the reacting cells were B lymphocytes. Fv determinants were not detected on the majority of T lymphocytes including cells with known T-helper cell activity. It is concluded that in mice, T cells do not express immunoglobulin v region framework determinants on their surface.
 ...
PMID:Variable region (Fv) determinants on mouse lymphocytes. 6 17

Cloning the correct genes that code for antibody-variable domains from hybridomas is often complicated by the presence of several immunoglobulin transcripts, some of them arising from a myeloma cell line. For the rapid functional evaluation of recombinant antibody fragments against cell-surface antigens, we established an efficient expression and screening system using phagemid antibodies and fixed cells. VL and VH-polymerase chain reaction (PCR) products, amplified from hybridoma cDNA, were cloned into the phagemid vector pSEX81. After transduction into E. coli and phage rescue, clones were tested for antigen binding using a phage-enzyme-linked immunosorbent assay (ELISA) procedure with whole cells fixed to ELISA wells. This procedure facilitated the successful cloning of a functional anti-CD20, single-chain antibody from hybridoma cDNA. The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for cancer treatment using immunoconjugates or bi-specific antibodies.
 ...
PMID:Selection of an anti-CD20, single-chain antibody by phage ELISA on fixed cells. 1034 8